Le Lézard
Classified in: Oil industry, Health, Science and technology
Subject: ACC

Aker ASA - Contemplating NOK Bond Issue


OSLO, Norway, Jan. 9, 2024 /PRNewswire/ -- Aker ASA, rated BBB- (stable) by Scope, has mandated Danske Bank, DNB Markets, Nordea and SEB as Joint Bookrunners to explore the possibility of one or more NOK senior unsecured fixed and/or floating bond issues with expected tenor of 5 years, subject to market conditions. In connection with the potential bond issue, Aker ASA may offer conditional buyback in its outstanding bond with ticker AKER15 (ISIN: NO0010868979).

For further information, please contact: 
Fredrik Berge, Head of Investor Relations Aker ASA
Tel: +47 45 03 20 90
E-mail: [email protected] 

This information is subject to the disclosure requirements pursuant to section 5 -12 the Norwegian Securities Trading Act.

 


These press releases may also interest you

at 18:27
Andreozzi + Foote is deeply troubled by revelations of sexual abuse perpetrated by Ramon Garcia against patients at Carbon Health Urgent Care in Jenkintown and possibly other locations. Our client, Jane Doe, bravely stepped forward to share her...

at 18:14
SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce the launch of the Sarcoma Centers Registry https://sarctrials.org/sarcoma-centers/, a comprehensive, global resource facilitating...

at 18:08
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced with great respect and sorrow the unexpected passing last night of...

at 18:02
It takes a unique, special kind of dedication to become a nurse. For the nurses in First Nations and Inuit communities, it takes strength, resiliency, expertise, and most importantly, heart. It takes an understanding of the complex environment of...

at 17:44
On Tuesday, May 7, 2024, The Center for Discovery® (TCFD, The Center) honored Edward C. Sweeney, TCFD Board Chair, at the 24th annual Evening of Discovery Gala. The Gala was hosted by Mo Rocca, CBS Sunday Morning Correspondent, Humorist, and Creator...

at 17:30
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibodyThe clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the...



News published on and distributed by: